INT299340

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 7
Disease Relevance 1.68
Pain Relevance 2.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (RPTOR) lysosome (RPTOR) cytoplasm (RPTOR)
RPTOR (Homo sapiens)
Pain Link Frequency Relevance Heat
mu opioid receptor 35 89.60 High High
opiate 63 89.16 High High
antagonist 70 88.56 High High
palliative 14 84.68 Quite High
Opioid 35 82.32 Quite High
MU agonist 7 78.96 Quite High
Morphine 21 76.96 Quite High
narcan 7 76.16 Quite High
analgesia 14 75.08 Quite High
Pain management 7 58.00 Quite High
Disease Link Frequency Relevance Heat
Disease 14 98.84 Very High Very High Very High
Cancer 42 97.16 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 7 83.28 Quite High
Constipation 7 81.16 Quite High
Appetite Loss 7 71.92 Quite High
Thrombocytopenia 7 70.80 Quite High
Hyperglycemia 7 70.08 Quite High
Anaemia 7 69.48 Quite High
Pressure And Volume Under Development 7 69.16 Quite High
Vomiting 7 68.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The effects of MNTX on inhibition of mTOR described in this manuscript go beyond VEGF receptor activation and extend to downstream signaling pathways.
Negative_regulation (inhibition) of mTOR
1) Confidence 0.53 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0 Pain Relevance 0.05
Therefore, we hypothesize that, in addition to its effects on GI motility, MNTX might have clinical utility by potentially lowering the therapeutic doses of mTOR inhibitors in the treatment of various diseases requiring angiogenesis including cancer.
Negative_regulation (inhibitors) of mTOR associated with cancer and disease
2) Confidence 0.39 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.47 Pain Relevance 0.77
We therefore hypothesized that methylnaltrexone could have synergistic effects with anti-angiogenic drugs (i.e. mTOR inhibitors).
Negative_regulation (inhibitors) of mTOR
3) Confidence 0.39 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.85 Pain Relevance 0.34
Both MNTX and temsirolimus block mTOR Complex 1 formation while only MNTX blocks mTOR Complex 2 formation (Figure 5-A).
Negative_regulation (block) of mTOR
4) Confidence 0.39 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0 Pain Relevance 0
Our results indicate that the synergistic effects of MNTX with mTOR inhibitors are achieved through inhibition of different components of a common VEGF-induced angiogenic signaling pathway.
Negative_regulation (inhibitors) of mTOR
5) Confidence 0.39 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.25 Pain Relevance 0.62
MNTX-induced Src inactivation results in inhibition of PI3 kinase and mTOR signaling required for Akt activation (serine/threonine phosphorylation).
Negative_regulation (inhibition) of mTOR
6) Confidence 0.39 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0 Pain Relevance 0.08
Both rapamycin and temsirolimus, a soluble ester analog of rapamycin, exert their action by binding to the intracellular protein, FKBP12, and inhibiting mTOR Complex 1 formation [38-40].
Negative_regulation (inhibiting) of mTOR
7) Confidence 0.39 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.11 Pain Relevance 0.75

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox